Advertisement
Research Article

A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle

  • Reijo Laaksonen mail,

    To whom correspondence should be addressed. E-mail: reijo.laaksonen@helsinki.fi (RL); matej.oresic@vtt.fi (MO)

    Affiliation: Research Unit, University Hospital of Tampere, Tampere, Finland

    X
  • Mikko Katajamaa,

    Affiliation: Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland

    X
  • Hannu Päivä,

    Affiliation: Department of Internal Medicine, University Hospital of Tampere, Tampere, Finland

    X
  • Marko Sysi-Aho,

    Affiliation: VTT Technical Research Centre of Finland, Espoo, Finland

    X
  • Lilli Saarinen,

    Affiliation: Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland

    X
  • Päivi Junni,

    Affiliation: Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland

    X
  • Dieter Lütjohann,

    Affiliation: Department of Clinical Pharmacology, University of Bonn, Bonn, Germany

    X
  • Joél Smet,

    Affiliation: Department of Pediatrics, Division of Pediatric Neurology and Metabolism, Ghent University Hospital, Ghent, Belgium

    X
  • Rudy Van Coster,

    Affiliation: Department of Pediatrics, Division of Pediatric Neurology and Metabolism, Ghent University Hospital, Ghent, Belgium

    X
  • Tuulikki Seppänen-Laakso,

    Affiliation: VTT Technical Research Centre of Finland, Espoo, Finland

    X
  • Terho Lehtimäki,

    Affiliations: Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Tampere, Finland, Centre for Laboratory Medicine, University Hospital of Tampere, Tampere, Finland, Medical School, University of Tampere, Tampere, Finland

    X
  • Juhani Soini,

    Affiliation: Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland

    X
  • Matej Orešič mail

    To whom correspondence should be addressed. E-mail: reijo.laaksonen@helsinki.fi (RL); matej.oresic@vtt.fi (MO)

    Affiliation: VTT Technical Research Centre of Finland, Espoo, Finland

    X
  • Published: December 20, 2006
  • DOI: 10.1371/journal.pone.0000097

About the Authors

Reijo Laaksonen
Research Unit, University Hospital of Tampere, Tampere, Finland
Mikko Katajamaa, Lilli Saarinen, Päivi Junni, Juhani Soini
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland
Hannu Päivä
Department of Internal Medicine, University Hospital of Tampere, Tampere, Finland
Marko Sysi-Aho, Tuulikki Seppänen-Laakso, Matej Orešič
VTT Technical Research Centre of Finland, Espoo, Finland
Dieter Lütjohann
Department of Clinical Pharmacology, University of Bonn, Bonn, Germany
Joél Smet, Rudy Van Coster
Department of Pediatrics, Division of Pediatric Neurology and Metabolism, Ghent University Hospital, Ghent, Belgium
Terho Lehtimäki
Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Tampere, Finland
Terho Lehtimäki
Centre for Laboratory Medicine, University Hospital of Tampere, Tampere, Finland
Terho Lehtimäki
Medical School, University of Tampere, Tampere, Finland

Corresponding Authors

Competing Interests

Drs. Orešič, Laaksonen, Päivä, and Lehtimäki are named inventors in a patent application to use metabolomics technology for screening of myopathy risk.

Author Contributions

Conceived and designed the experiments: MO RL. Performed the experiments: TS HP JS. Analyzed the data: MO RL MK MS LS PJ. Contributed reagents/materials/analysis tools: MO TS HP DL JS Rv TL JS. Wrote the paper: MO RL MK MS.